Brousset P, al Saati T, Chaouche N, Zenou R C, Schlaifer D, Chittal S, Delsol G
Laboratoire du Groupe d'Etude des Lymphomes Malins (CNRS, CIGH), Toulouse, France.
Blood. 1997 Jan 1;89(1):26-31.
We used the recently described sensitive and rapid detection assay called telomeric repeat amplification protocol (TRAP) to detect telomerase activity in lymphoblastoid (n = 5) and lymphoma cell lines (n = 7), hyperplastic lymph nodes (n = 6) and tonsils (n = 5), and tissues involved by non-Hodgkin's lymphoma (NHL) (n = 43) and Hodgkin's disease (HD) (n = 14). Clearly evident telomerase activity was found in all lymphoblastoid and lymphoma cell lines, and in 34 of 43 cases (80%) of NHL. These results were expected because of the proliferative and immortal nature of the cell lines and most malignant cells. However, positive results were obtained with the TRAP assay in all hyperplastic lymph nodes and tonsils, which raises the issue of derepression of telomerase activity during an immune response. Telomerase activity alone therefore does not distinguish malignant lymphoid proliferations from reactive states. Telomerase activity was detected in only 1 of 14 cases (7%) of lymphoid tissues involved by HD. Eight of the 13 negative cases were considered to be interpretable because of the lack (3 of 13 cases) or low level (5 of 13 cases) of telomerase inhibition. The five remaining cases could not be evaluated because of their telomerase inhibitor content. The findings imply either transient or very low levels of telomerase activity in HD or that HD for the greater part is a telomerase-independent neoplasm. Microdissection studies are needed to identify subsets of cells carrying telomerase activity in both reactive and neoplastic lymphoid tissues.
我们使用了最近描述的一种灵敏且快速的检测方法——端粒重复序列扩增法(TRAP),来检测淋巴母细胞系(n = 5)和淋巴瘤细胞系(n = 7)、增生性淋巴结(n = 6)和扁桃体(n = 5)以及非霍奇金淋巴瘤(NHL)累及组织(n = 43)和霍奇金病(HD)累及组织(n = 14)中的端粒酶活性。在所有淋巴母细胞系和淋巴瘤细胞系以及43例NHL中的34例(80%)中均发现了明显的端粒酶活性。由于细胞系和大多数恶性细胞具有增殖和永生化特性,这些结果在意料之中。然而,在所有增生性淋巴结和扁桃体中,TRAP检测均得到了阳性结果,这就引发了免疫反应过程中端粒酶活性去抑制的问题。因此,仅端粒酶活性并不能区分恶性淋巴增殖与反应性状态。在HD累及的14例淋巴组织中,仅1例(7%)检测到端粒酶活性。13例阴性病例中的8例被认为是可解释的,原因是端粒酶抑制缺乏(13例中的3例)或水平较低(13例中的5例)。其余5例由于端粒酶抑制剂含量而无法评估。这些发现意味着HD中端粒酶活性要么是短暂的,要么水平非常低,或者HD在很大程度上是一种不依赖端粒酶的肿瘤。需要进行显微切割研究,以确定反应性和肿瘤性淋巴组织中携带端粒酶活性的细胞亚群。